RYANODEX (dantrolene sodium) by Eagle Pharmaceuticals is clinical pharmacology in isolated nerve-muscle preparation, dantrolene sodium has been shown to produce relaxation by affecting the contractile response of the skeletal muscle at a site beyond the myoneural junction, directly on the muscle itself. Approved for heat stroke. First approved in 2014.
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
RYANODEX (dantrolene sodium) is an IV skeletal muscle relaxant that dissociates excitation-contraction coupling by interfering with calcium release from the sarcoplasmic reticulum. It is indicated for malignant hyperthermia crisis, heat stroke, and drug toxicity. The drug acts directly on muscle tissue beyond the neuromuscular junction with a mean half-life of 8.7 hours.
RYANODEX is in peak commercial stage with moderate competitive pressure (30%), positioning it as a stable revenue contributor for Eagle Pharmaceuticals with established field and medical affairs infrastructure.
CLINICAL PHARMACOLOGY In isolated nerve-muscle preparation, dantrolene sodium has been shown to produce relaxation by affecting the contractile response of the skeletal muscle at a site beyond the myoneural junction, directly on the muscle itself. In skeletal muscle, dantrolene sodium dissociates…
Worked on RYANODEX at Eagle Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Study to Assess the Efficacy and Safety of Ryanodex as Adjuvant Treatment in Subjects With EHS
Efficacy and Safety Study of Ryanodex as Adjuvant Treatment in Subjects With Psychostimulant Drug-Induced Toxicity (PDIT)
Efficacy and Safety of Ryanodex® (EGL-4104) as Adjuvant Treatment in Subjects With Exertional Heat Stroke (EHS)
RYANODEX offers stable career opportunities in a specialized, high-acuity indication with mission-critical patient impact; roles focus on hospital formulary penetration, anesthesia provider education, and clinical evidence dissemination. Career advancement depends on geographic market development and competitive defense against generics and Pfizer's established DANTRIUM.